WASHINGTON — President Donald Trump put his personal stamp on the American healthcare system Thursday night, launching TrumpRx.gov, a new government portal designed to bypass insurance middlemen and deliver prescription drugs at prices matched to the lowest international rates.
“This is a very big deal,” Trump declared during the primetime event at the White House on Feb. 5. “People are going to save a lot of money and be healthy. We are finally ending the days where American patients subsidize the rest of the world. Today, we put America First, and that means American prices come first.”
Standing at a podium flanked by backlit displays of the new website, the President unveiled a list of over 40 medications—ranging from insulin and heart medication to high-demand fertility and weight-loss drugs—that he said would now be available at “steeply discounted” rates.
The launch is the culmination of the administration’s aggressive pursuit of “Most Favored Nation” (MFN) status, a policy leveraging U.S. market access to force pharmaceutical giants to sell drugs to Americans at the same prices they offer to nations like Germany or France.
The “Infomercial” Rollout
The event, held in the White House’s South Court Auditorium, felt less like a policy briefing and more like a Silicon Valley product launch—a deliberate stylistic choice driven by Joe Gebbia, the Airbnb co-founder whom Trump appointed as Director of the National Design Studio.
Gebbia joined Trump on stage, alongside Dr. Mehmet Oz, the Administrator for the Centers for Medicare & Medicaid Services (CMS), and Health and Human Services Secretary Robert F. Kennedy Jr.
Gebbia, tasked with modernizing the federal government’s digital interface, ran a live demonstration of TrumpRx.gov on a massive screen. The site features a clean, minimalist aesthetic, starkly different from typical government portals.
“Today you can now get access to these discounted − steeply discounted − prices,” said Oz, who acted as the evening’s master of ceremonies. “All the hard work that the president and the administration have done now is yours, but you have to go check TrumpRx.gov.”
Gebbia highlighted the user experience, noting that patients do not need insurance pre-authorization to access these specific prices. He demonstrated how a user could search for a drug, download a coupon to a digital wallet (like Apple Pay), and present it at a pharmacy.
“Design is policy,” Gebbia said, scrolling through the mobile interface. “If you can’t figure out how to get the discount, the discount doesn’t exist. We made this as easy as booking a room.”
“Trump Babies” and the Fertility Push
In a moment that quickly went viral, the administration leaned heavily into family economics. Dr. Oz directed the President’s attention to the site’s listing for Gonal-F, a critical and expensive fertility medication used in IVF treatments.
On TrumpRx, the drug was listed at an 83% discount compared to the standard U.S. list price.
“Mr. President, one in three families is having trouble having a baby,” Oz told Trump. “We’re going to have a lot of Trump babies with these costs.”
The comment underscored a strategic pivot for the administration. By targeting fertility drugs, the White House is addressing a major financial pain point for young families and the suburban demographic—key voting blocs for the upcoming 2026 midterm elections. The site lists drastic reductions for several other fertility aids, including Cetrotide and Ovidrel, aiming to make IVF more accessible to the middle class.
Cracking the Weight Loss Market
Beyond fertility, the site takes aim at the country’s most explosive drug category: GLP-1 weight loss medications.
The high cost of drugs like Ozempic, Wegovy, and Zepbound—often exceeding $1,000 per month without insurance—has been a major point of contention. Insurers frequently deny coverage for these drugs when used solely for weight loss, leaving millions of Americans to pay full price out-of-pocket.
TrumpRx lists these drugs with “Most Favored Nation” pricing that mirrors European markets.
- Wegovy: Listed at approximately $149 per month.
- Ozempic: Dropped to $350 for cash-paying patients.
- Zepbound: Listed at roughly $346.
“We have broken the cartel pricing on obesity,” Trump asserted. “Why should Denmark pay $100 for a drug that costs our citizens $1,000? We told the companies: if you want access to the American market, you give us the American price.”
How the Deal Was Done
The prices listed on TrumpRx reflect agreements negotiated with more than a dozen major pharmaceutical companies, including Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, Gilead, GSK, Merck, Novartis, Novo Nordisk, Pfizer, and Sanofi.
According to White House insiders, these deals were not entirely voluntary. Throughout 2025, President Trump reportedly threatened steep tariffs on raw material imports and finished goods for companies that refused to align their U.S. pricing with their international rates.
“The leverage was simple,” said a senior policy advisor. “You can’t sell to American seniors at a 500% markup anymore. The President made it clear that the era of the American consumer subsidizing global R&D is over.”
The result is a hybrid model. TrumpRx.gov acts as a clearinghouse. It aggregates direct-to-consumer discount programs and negotiates a standardized “cash” price, which manufacturers agree to honor. By centralizing these offers on a .gov domain, the administration provides a stamp of legitimacy and a single point of entry for confused consumers.
The “MAHA” Influence
The presence of Robert F. Kennedy Jr. at the launch highlighted the administration’s eclectic health coalition. As the architect of the “Make America Healthy Again” (MAHA) movement, Kennedy has historically been a fierce critic of the pharmaceutical industry.
However, Kennedy framed TrumpRx as a necessary step to stop financial predation while his department works on long-term health goals.
“The pharmaceutical complex has preyed on American metabolic health for profit,” Kennedy said in a statement supporting the launch. “While we work to remove toxic foods and heal our soil, we must stop the bleeding of American family budgets. Fair pricing is the first step in breaking the stranglehold these companies have on our economy.”
Industry and Political Reactions
The healthcare industry has reacted with cautious cooperation. By participating in TrumpRx, pharmaceutical manufacturers are effectively bypassing Pharmacy Benefit Managers (PBMs)—the middlemen who negotiate drug prices for insurers and take a cut of the profits.
“This is the industry realizing that the PBM model is under siege,” said a Wall Street biotech analyst. “They are partnering with Trump to kill the middleman. It allows them to lower the consumer price without necessarily losing revenue, because they aren’t paying the PBM rebates.”
Politically, the move is timed for maximum impact ahead of the 2026 midterms. Democrats have criticized the plan as “governing by coupon,” arguing that it lacks the permanence of legislation.
“President Trump is offering discounts that can be revoked at any time by corporate boards,” said Senate Minority Leader Chuck Schumer. “We need binding legislation, not a QR code.”
Yet, the administration is betting that the immediate savings will speak louder than legislative procedure.
“They said we couldn’t do it,” Trump told the crowd as the event concluded. “They said the prices are set in stone. Well, we took a hammer to the stone. And we are just getting started.”